Which drug first? new trial aims to optimize breast cancer treatment sequence
NCT ID NCT07368543
First seen Jan 31, 2026 · Last updated Apr 28, 2026 · Updated 11 times
Summary
This study tests the best order of two powerful targeted drugs (sacituzumab govitecan and trastuzumab deruxtecan) in people with HER2-low, TROP2-high metastatic breast cancer. About 216 participants will be randomly assigned to start with one drug and switch to the other upon progression. The goal is to see which sequence controls the cancer longer and to identify biomarkers that predict response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.